Literature DB >> 8760595

Scatter factor expression and regulation in human glial tumors.

E M Rosen1, J Laterra, A Joseph, L Jin, A Fuchs, D Way, M Witte, M Weinand, I D Goldberg.   

Abstract

Scatter factor (SF) (also known as hepatocyte growth factor [HGF]) is a cytokine that induces cell motility in vitro and angiogenesis in vivo. SF appears to be a determinant of the malignant phenotype in certain systemic cancers. We detected SF in extracts prepared from human gliomas, with the highest levels found in malignant tumors. Human glioblastoma cells expressed both SF and its receptor (c-met protein) in vivo, as demonstrated by immunohistochemistry. Consistent with these observations, we found moderate to high levels of production of immunoreactive and biologically active SF by cultured human glioblastoma cells (3 of 8 lines) and by neural microvascular endothelial cells (NMVEC) (3 of 3 lines). SF stimulated the proliferation of glioblastoma and NMVEC cell lines by paracrine or autocrine mechanisms. Conditioned medium (CM) from both glioblastoma and NMVEC cells contained SF-inducing factor (SF-IF) activity, defined by its ability to stimulate SF production in an indicator cell line (MRC5 human fibroblasts). This activity consisted of a high-molecular-weight (> 30 kDa), heat-sensitive component and a low-molecular weight (< 30 kDa), heat-stable component. Furthermore, glioblastoma CM stimulated NMVEC SF production, and NMVEC CM stimulated glioblastoma cell SF production, by 3- to 6-fold in each case. Our findings demonstrate that SF-dependent interactions between glioma cells, and between glioma cells and endothelium, can contribute to the heterogeneous proliferative and angiogenic phenotypes of malignant gliomas in vivo.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8760595     DOI: 10.1002/(SICI)1097-0215(19960717)67:2<248::AID-IJC16>3.0.CO;2-7

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  37 in total

1.  A phase 1 study of the c-Met inhibitor, tivantinib (ARQ197) in children with relapsed or refractory solid tumors: A Children's Oncology Group study phase 1 and pilot consortium trial (ADVL1111).

Authors:  James I Geller; John P Perentesis; Xiaowei Liu; Charles G Minard; Rachel A Kudgus; Joel M Reid; Elizabeth Fox; Susan M Blaney; Brenda J Weigel
Journal:  Pediatr Blood Cancer       Date:  2017-04-27       Impact factor: 3.167

Review 2.  Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis.

Authors:  Roger Abounader; John Laterra
Journal:  Neuro Oncol       Date:  2005-10       Impact factor: 12.300

3.  89Zr-DFO-AMG102 Immuno-PET to Determine Local Hepatocyte Growth Factor Protein Levels in Tumors for Enhanced Patient Selection.

Authors:  Eric W Price; Kathryn E Carnazza; Sean D Carlin; Andrew Cho; Kimberly J Edwards; Kuntal K Sevak; Jonathan M Glaser; Elisa de Stanchina; Yelena Y Janjigian; Jason S Lewis
Journal:  J Nucl Med       Date:  2017-03-09       Impact factor: 10.057

4.  An orally bioavailable c-Met kinase inhibitor potently inhibits brain tumor malignancy and growth.

Authors:  Fadila Guessous; Ying Zhang; Charles diPierro; Lukasz Marcinkiewicz; Jann Sarkaria; David Schiff; Sean Buchanan; Roger Abounader
Journal:  Anticancer Agents Med Chem       Date:  2010-01       Impact factor: 2.505

5.  MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes.

Authors:  Yunqing Li; Fadila Guessous; Ying Zhang; Charles Dipierro; Benjamin Kefas; Elizabeth Johnson; Lukasz Marcinkiewicz; Jinmai Jiang; Yanzhi Yang; Thomas D Schmittgen; Beatriz Lopes; David Schiff; Benjamin Purow; Roger Abounader
Journal:  Cancer Res       Date:  2009-09-22       Impact factor: 12.701

Review 6.  The multiple paths towards MET receptor addiction in cancer.

Authors:  Leslie Duplaquet; Zoulika Kherrouche; Simon Baldacci; Philippe Jamme; Alexis B Cortot; Marie-Christine Copin; David Tulasne
Journal:  Oncogene       Date:  2018-03-19       Impact factor: 9.867

7.  Hepatocyte growth factor and sonic Hedgehog expression in cerebellar neural progenitor cells costimulate medulloblastoma initiation and growth.

Authors:  Mandy J Binning; Toba Niazi; Carolyn A Pedone; Bachchu Lal; Charles G Eberhart; K Jin Kim; John Laterra; Daniel W Fults
Journal:  Cancer Res       Date:  2008-10-01       Impact factor: 12.701

8.  Radiosensitization of glioma cells by modulation of Met signalling with the hepatocyte growth factor neutralizing antibody, AMG102.

Authors:  Ian M Buchanan; Tamalee Scott; Anita T Tandle; William E Burgan; Teresa L Burgess; Philip J Tofilon; Kevin Camphausen
Journal:  J Cell Mol Med       Date:  2010-07-12       Impact factor: 5.310

9.  Vascular gene expression in nonneoplastic and malignant brain.

Authors:  Stephen L Madden; Brian P Cook; Mariana Nacht; William D Weber; Michelle R Callahan; Yide Jiang; Michael R Dufault; Xiaoming Zhang; Wen Zhang; Jennifer Walter-Yohrling; Cecile Rouleau; Viatcheslav R Akmaev; Clarence J Wang; Xiaohong Cao; Thia B St Martin; Bruce L Roberts; Beverly A Teicher; Katherine W Klinger; Radu-Virgil Stan; Brenden Lucey; Eleanor B Carson-Walter; John Laterra; Kevin A Walter
Journal:  Am J Pathol       Date:  2004-08       Impact factor: 4.307

10.  The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma.

Authors:  Tanguy Y Seiwert; Ramasamy Jagadeeswaran; Leonardo Faoro; Varalakshmi Janamanchi; Vidya Nallasura; Mohamed El Dinali; Soheil Yala; Rajani Kanteti; Ezra E W Cohen; Mark W Lingen; Leslie Martin; Soundararajan Krishnaswamy; Andres Klein-Szanto; James G Christensen; Everett E Vokes; Ravi Salgia
Journal:  Cancer Res       Date:  2009-03-24       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.